The Crucial Role of Phase I Clinical Trials in Advancing Medicine; by David Walling, PhD The journey from a promising scientific discovery to a safe and effective medication available to the public is a complex and rigorous process. At the heart of this...
News at CenExel
Advancements in Vaccines: Bridging the Past and Future
Advancements in Vaccines: Bridging the Past and Future - by Nelia Sanchez-Crespo, MD The history of vaccines is a testament to the incredible progress we've made in protecting humanity against infectious diseases. From the invention of the smallpox...
The Placebo-Control Reminder Script and Supplementary Instrument Properties: Evaluation of Face and Content Validity
CenExel is proud to highlight the poster presented at the International Society for CNS Clinical Trials and Methodology (ISCTM) Annual Scientific Meeting, February 2023, Washington, DC. ABSTRACT Introduction: The Placebo-Control Reminder Script (PCRS) is an...
CenExel Psychedelic Facilitators Undergoing Premier Certification Training
Our Clinical Sciences team, comprised of Dr. Larry Ereshefsky, Dr. Brett English, Dr. Robert Litman, along with Principal Investigators Dr. Djouher Hough, and Dr. Haig Goenjian, have developed fit for purpose go-to-clinic strategies encompassing pharmacology, regulatory, and protocol-development consultation services, as well as meticulous clinical trial execution.
Further Exploration of the Placebo-Control Reminder Script: Essential Perspectives from the End User
CenExel is proud to highlight the poster presented at the Annual CNS Summit, November 2022, Boca Raton, FL. ABSTRACT Introduction: Placebo and nocebo responses continue to hinder potential treatment effects (Haflioadottiret al., 2021). The Placebo-Control Reminder...
Placebo-Control Reminder Script
General medicine studies are not immune to the placebo effect, where 30-40% of patients report improved subjective and objective outcomes in general medical studies (Hrobjartsson & Gotzsche, 2001). The high placebo response has been shown to be increasing as time progresses (Kemp et al., 2010; Loebel et al., 2010; Rief et al., 2009; Tuttle et al., 2015), with such ramifications as several pharma companies reducing or closing their psychiatric as well as general medicine R&D, increased costs for drug development, more inconclusive and failed trials, and delays in the development of new medications (Alphs et al., 2012).